Zhejiang Huahai Pharmaceutical Co Ltd (Huahai Pharmaceuticals) develops and markets active pharmaceutical ingredients (APIs), intermediates and formulations. It carries out the commercial production of captopril, enalapril and lisinopril. The company classifies its product and service portfolio into five divisions, namely, finished pharmaceutical products; APIs and intermediates and import and export trade services. Through finished pharmaceutical division, the company offers products in central neurological, cardiovascular, anti-viral and others. Few of its products include ropinirole tablets, donepezil HCL tablets, levetiracetam tablets, paroxetine tablets and escitalopram tablets. Under its API and intermediates division, the company offers an array of APIs for development and treatment in therapeutic areas such as cardiovascular central nerve system and anti-viral. These include ace inhibitors, angiotensin II receptor antagonists, anti-AIDS, anti-depressants, antihistamines, antihypertensives, and antipsychotics. The company offers import and export trade services through its subsidiary, Jiangsu Galaxy Imp and Exp Corp. It assists its clients in raw material purchase and export trade services in the food, beverage, dietary supplement and personal care industry. The company incurred capital expenditure of CNY2,316.28 million in FY2022, which indicates an increase of 4.9% YoY compared to CNY2,434.46 million in the FY2021.

Huahai Pharmaceuticals conducts R&D activities through three centers: US R&D, Shanghai R&D and Linhai R&D. The US R&D center conducts frontier pharmaceutical technology intelligence and the development of innovative drugs. The Shanghai R&D center conducts research of patentable know-how, development of me-too drugs and new dosage forms. The Linhai R&D center focuses on the improvement of API manufacturing and development of formulation processes. In FY2022, the company incurred R&D expenses of CNY833.5 million, which as a percentage of revenue, stood at 10.08%.